Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
Authors:
Open Access
- 9 January 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 1037816
Abstract
Background: Vortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine in a cohort of patients with MDD and comorbid Alzheimer’s disease participating in a large post-marketing surveillance study in South Korea.Methods: Subgroup analysis of a 6-month, prospective, multicenter, non-interventional cohort study in outpatients with MDD with a pre-baseline diagnosis of Alzheimer’s disease receiving vortioxetine in routine care settings (n = 207). Patients were assessed at baseline and after 8 weeks; a subset of patients was also assessed after 24 weeks. Depression severity was assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression (CGI) scale, cognitive symptoms using the Perceived Deficits Questionnaire–Depression, Korean version (PDQ-K), and cognitive performance using the Digit Symbol Substitution Test (DSST).Results: Most patients were receiving a mean daily vortioxetine dose of 5 mg/day (174/190 patients; 91.6%). After 24 weeks of vortioxetine treatment, 71.4% of patients (40/56) had experienced overall clinical improvement (i.e., CGI–Improvement score ≤3) and 51.9% (28/54) had achieved remission from depressive symptoms (i.e., MADRS total score ≤10 points). Respective mean changes in MADRS, PDQ-K, and DSST total scores from baseline to week 24 were −11.5 (p < 0.0001), −5.1 (p = 0.03), and +3.8 points (p = 0.0524). Adverse events were reported by 27 patients (13.0%) and were mostly mild (89.2%).Conclusion: Patients with MDD and comorbid Alzheimer’s disease receiving vortioxetine in routine care settings in South Korea demonstrated clinically meaningful improvements in depressive symptoms, cognitive symptoms, and objective cognitive performance over the 6-month treatment period. Treatment with vortioxetine was well tolerated in this patient cohort, with reported adverse events consistent with the established tolerability profile of vortioxetine.Keywords
This publication has 62 references indexed in Scilit:
- Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in ratsPharmacology Biochemistry and Behavior, 2013
- Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology studyEuropean Neuropsychopharmacology, 2013
- A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorderInternational Clinical Psychopharmacology, 2012
- Midlife vs Late-Life Depressive Symptoms and Risk of DementiaArchives of General Psychiatry, 2012
- Depression in dementiaCurrent Opinion in Psychiatry, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- The clinical relevance of changes in the Montgomery–Asberg Depression Rating Scale using the minimum clinically important difference approachCurrent Medical Research and Opinion, 2008
- Depression and Risk for Alzheimer DiseaseArchives of General Psychiatry, 2006
- The Construct of Minor and Major Depression in Alzheimer’s DiseaseAmerican Journal of Psychiatry, 2005
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979